Asia Pacific Drug Development Market Size, Share & Trends Analysis Report By Mode (In house, Outsourced), By Process Step (DMPK, Safety Assessment), By Therapeutic Area, And Segment Forecasts, 2019 - 2026

The Asia Pacific drug development market is expected to reach USD 62.46 billion by 2026 and is projected to expand at a CAGR of 6.54%, according to a new report by Grand View Research, Inc. Challenges pertaining to the escalating research costs and shrinking revenue faced by major pharma companies have led to the significant expansion of Asian drug development sector. A rapidly expanding healthcare infrastructure, low operating costs, and a growing patient population have contributed to the recognition of Asian countries as an ideal site for low-cost drug development.

Furthermore, the growing acceptance of clinical trial data generated in Asia by Western drug regulators, including the EMA and U.S. FDA, is one of the key market drivers. This is primarily because of the increasing similarities of Asian disease demographics to that of the Western nations.

Various government policies have been formulated to promote implementation of digital and advanced analytics, such as artificial intelligence, in the region. Moreover, the pharma companies are collaborating with AI-based companies to leverage algorithms and cloud computing to transform their drug development process.

The contract research organizations are experiencing increasing levels of interest in Asian countries from their U.S. -based client base. This is a testament to the lucrative growth of Asia Pacific market, driving its growth in the coming years.

Further key findings from the report suggest:

• Outsourced mode of pharmaceutical development led the market and is expected to maintain its dominance throughout the forecast period, due to the fact that the companies are investing or redirecting their significant investments from already existing R&D centers in Europe and U.S. to emerging centers in Asia

• Analytical & stability studies captured the largest revenue share in the market, due to the high usage of advanced and relative expensive technologies such as Electron Paramagnetic Resonance (EPR) spectroscopy

• Oncology is estimated to be the highest revenue generating segment, due to the presence of a substantial number of cancer targeting therapeutics in clinical development phase. This segment is expected to maintain a fast CAGR during the forecast period owing to wide acceptance of personalized therapy in cancer treatment

• Strong government support for innovation and large and diverse domestic pharma industry of China has led to the dominance of China over other countries in the Asia Pacific drug development market

• Furthermore, the launch of several start-ups in India is expected to serve as a significant source of revenue to the Indian pharmaceutical industry

• Some key contract service providers operating in the Asia Pacific drug development market are Eurofins Advinus; Covance Inc.; Celerion; and Parexel International Corporation. With the rising trend of outsourcing pharmaceutical manufacturing, these CROs are expected to witness great organic revenue growth

• In house global pharmaceutical manufacturers such as Pfizer and AstraZeneca are also striving to gain competitive ground in the Asian market

Table of content

Chapter 1 Executive Summary

• 1.1 Market Snapshot

Chapter 2 Research Methodology

• 2.1 Information Procurement
• 2.2 Information or Data Analysis
• 2.3 Market Formulation & Validation

Chapter 3 Market Variables, Trends, & Scope

• 3.1 Market Segmentation & Scope
  • 3.1.1 Market driver analysis
    • 3.1.1.1 Rising pharma R&D outsourcing
    • 3.1.1.2 Growing accessibility to Artificial Intelligence (AI) for pharmaceutical research
    • 3.1.1.3 Expansion in the global drug developer in Asian market
  • 3.1.2 Market restraint analysis
    • 3.1.2.1 Different approval timelines
    • 3.1.2.1 Presence of well-established players in western market
• 3.2 Penetration & Growth Prospect Mapping For Process Step Scope, 2018
• 3.3 Asia Pacific Drug Development Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
• 3.4 Industry Analysis - Porter's

Chapter 4 Asia Pacific Drug Development Market Categorization: Mode Estimates & Trend Analysis

• 4.1 Asia Pacific Drug Development Market: Mode Movement Analysis
• 4.2 In house
  • 4.2.1 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
• 4.3 Outsourced
  • 4.3.1 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)

Chapter 5 Asia Pacific Drug Development Market Categorization: Process Step Estimates & Trend Analysis

• 5.1 Asia Pacific Drug Development Market: Process Step Movement Analysis
• 5.2 Process Research Development
  • 5.2.1 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
• 5.3 Formulation
  • 5.3.1 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
• 5.4 Analytical & stability studies
  • 5.4.1 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
• 5.5 Drug Metabolism and Pharmacokinetics (DMPK)
  • 5.5.1 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
• 5.6 Safety Assessment (Toxicology)
  • 5.6.1 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
• 5.7 Regulatory Compliance
  • 5.7.1 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
• 5.8 Packaging
  • 5.8.1 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)

Chapter 6 Asia Pacific Drug Development Market Categorization: Therapeutic Area Estimates & Trend Analysis

• 6.1 Asia Pacific Drug Development Market: Therapeutic Area Movement Analysis
• 6.2 Oncology
  • 6.2.1 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
• 6.3 Inflammation & Immunology
  • 6.3.1 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
• 6.4 Cardiology
  • 6.4.1 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
• 6.5 Neuroscience
  • 6.5.1 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
• 6.6 Others
  • 6.6.1 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)

Chapter 7 Asia Pacific Drug Development Market Categorization: Country Estimates & Trend Analysis, by Mode, Process Step, & Therapeutic Area

• 7.1 Asia Pacific Drug Development Market Share, By Country, 2018 & 2026
• 7.2 India
  • 7.2.1 India drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.2.2 India drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.2.3 India drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.3 China
  • 7.3.1 China drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.3.2 China drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.3.3 China drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.4 Singapore
  • 7.4.1 Singapore drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.4.2 Singapore drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.4.3 Singapore drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.5 Japan
  • 7.5.1 Japan drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.5.2 Japan drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.5.3 Japan drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.6 South Korea
  • 7.6.1 South Korea drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.6.2 South Korea drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.6.3 South Korea drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.7 Indonesia
  • 7.7.1 Indonesia drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.7.2 Indonesia drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.7.3 Indonesia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.8 Australia
  • 7.8.1 Australia drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.8.2 Australia drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.8.3 Australia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.9 Malaysia
  • 7.9.1 Malaysia drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.9.2 Malaysia drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.9.3 Malaysia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
• 7.10 Vietnam
  • 7.10.1 Vietnam drug development market, by mode, 2015 - 2026 (USD Million)
  • 7.10.2 Vietnam drug development market, by process step, 2015 - 2026 (USD Million)
  • 7.10.3 Vietnam drug development market, by therapuetic area, 2015 - 2026 (USD Million)

Chapter 8 Asia Pacific Drug Development Market: Competitive Landscape

• 8.1 Strategy Framework
• 8.2 Market Participant Categorization
• 8.3 Company Profiles
  • 8.3.1 Samsung BioLogics
    • 8.3.1.1 Company overview
    • 8.3.1.2 Financial performance
    • 8.3.1.3 Product benchmarking
    • 8.3.1.4 Strategic initiatives
  • 8.3.2 WuXi Biologics
    • 8.3.2.1 Company overview
    • 8.3.2.2 Financial performance
    • 8.3.2.3 Product benchmarking
    • 8.3.2.4 Strategic initiatives
  • 8.3.3 Celltrion Inc.
    • 8.3.3.1 Company overview
    • 8.3.3.2 Financial performance
    • 8.3.3.3 Product benchmarking
    • 8.3.3.4 Strategic initiatives
  • 8.3.4 PT Kalbe Farma Tbk
    • 8.3.4.1 Company overview
    • 8.3.4.2 Financial performance
    • 8.3.4.3 Product benchmarking
    • 8.3.4.4 Strategic initiatives
  • 8.3.5 Eurofins Advinus
    • 8.3.5.1 Company overview
    • 8.3.5.2 Financial performance
    • 8.3.5.3 Product benchmarking
    • 8.3.5.4 Strategic initiatives
  • 8.3.6 Covance Inc.
    • 8.3.6.1 Company overview
    • 8.3.6.2 Financial performance
    • 8.3.6.3 Product benchmarking
    • 8.3.6.4 Strategic initiatives
  • 8.3.7 Celerion
    • 8.3.7.1 Company overview
    • 8.3.7.2 Financial performance
    • 8.3.7.3 Product benchmarking
    • 8.3.7.4 Strategic initiatives
  • 8.3.8 Parexel International Corporation
    • 8.3.8.1 Company overview
    • 8.3.8.2 Financial performance
    • 8.3.8.3 Product benchmarking
    • 8.3.8.4 Strategic initiatives
  • 8.3.9 GVK Biosciences Private Limited
    • 8.3.9.1 Company overview
    • 8.3.9.2 Financial performance
    • 8.3.9.3 Product benchmarking
    • 8.3.9.4 Strategic initiatives
  • 8.3.10 Vifor Pharma Asia Pacific Pte. Ltd
    • 8.3.10.1 Company overview
    • 8.3.10.2 Financial performance
    • 8.3.10.3 Financial performance
    • 8.3.10.4 Product benchmarking

List of Tables

• TABLE 1 ASEAN guidelines on stability study and shelf-life of traditional medicines
• TABLE 2 Regulatory bodies governing drug development in Asia Pacific
• TABLE 3 India drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 4 India drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 5 India drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 6 China drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 7 China drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 8 China drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 9 Singapore drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 10 Singapore drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 11 Singapore drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 12 Japan drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 13 Japan drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 14 Japan drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 15 South Korea drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 16 South Korea drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 17 South Korea drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 18 Indonesia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 19 Indonesia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 20 Indonesia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 21 Australia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 22 Australia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 23 Australia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 24 Malaysia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 25 Malaysia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 26 Malaysia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
• TABLE 27 Vietnam drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
• TABLE 28 Vietnam drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
• TABLE 29 Vietnam drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)

List of Figures

• FIG. 1 Market snapshot
• FIG. 2 Market research process
• FIG. 3 Information procurement
• FIG. 4 Primary research pattern
• FIG. 5 Market research approaches
• FIG. 6 Value chain based sizing & forecasting
• FIG. 7 QFD modelling for market share assessment
• FIG. 8 Market trends & outlook
• FIG. 9 Market segmentation & scope
• FIG. 10 Market driver relevance analysis (Current & future impact)
• FIG. 11 Market restraint relevance analysis (Current & future impact)
• FIG. 12 Penetration & growth prospect mapping for Process Step Scope, 2018
• FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
• FIG. 14 Porter's Five Forces Analysis
• FIG. 15 Asia Pacific drug development market: Mode outlook key takeaways
• FIG. 16 Asia Pacific drug development market: Mode movement analysis
• FIG. 17 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
• FIG. 18 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)
• FIG. 19 Asia Pacific drug development market: Process step outlook key takeaways
• FIG. 20 Asia Pacific drug development market: Process step movement analysis
• FIG. 21 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
• FIG. 22 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
• FIG. 23 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
• FIG. 24 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
• FIG. 25 Toxicology studies during drug development
• FIG. 26 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
• FIG. 27 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
• FIG. 28 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)
• FIG. 29 Asia Pacific drug development market: Therapeutic area outlook key takeaways
• FIG. 30 Asia Pacific drug development market: Therapeutic area movement analysis
• FIG. 31 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
• FIG. 32 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
• FIG. 33 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
• FIG. 34 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
• FIG. 35 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)
• FIG. 36 Regional market place: Key takeaway
• FIG. 37 Asia Pacific drug development market: Country outlook, 2018 & 2026
• FIG. 38 India drug development market, 2015 - 2026 (USD Million)
• FIG. 39 India drug development market, 2015 - 2026 (USD Million)
• FIG. 40 Singapore drug development market, 2015 - 2026 (USD Million)
• FIG. 41 Japan drug development market, 2015 - 2026 (USD Million)
• FIG. 42 South Korea drug development market, 2015 - 2026 (USD Million)
• FIG. 43 Indonesia drug development market, 2015 - 2026 (USD Million)
• FIG. 44 Australia drug development market, 2015 - 2026 (USD Million)
• FIG. 45 Malaysia drug development market, 2015 - 2026 (USD Million)
• FIG. 46 Vietnam drug development market, 2015 - 2026 (USD Million)
• FIG. 47 Strategy framework
• FIG. 48 Market participant categorization